STROKE PREVENTION IN NON-VALVULAR FORM OF ATRIAL FIBRILLATION
https://doi.org/10.18705/2311-4495-2014-0-2-97-104
Abstract
The article presents the analysis of modern approaches to risk stratification of development of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation and also risk stratification of major bleeding on a background of antithrombotic therapy. The comparative characteristic of new oral anticoagulants is given.
About the Author
Tatiana N. Novikova
North-Western State Medical University n.a. I.I. Mechnikov
Russian Federation
Russian Federation
References
1. Anderson K.K., Olsen T.S., Dehlendorff C. et al. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors // Stroke. - 2009. - Vol. 40. - P. 2068-2072.
2. Savelieva I., Bajpai A., Camm A.J. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices // Ann. Med. - 2007. - Vol. 39. - P. 71-91.
3. Emmerich J., Heuzey J.-Y.L., Bath P.M.W., Connolly S.J. Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. // Eur. Heart. J. - 2005. - Vol. 7, Supp. C. - P. C28-C33.
4. Hannon N., Sheehan O., Kelly L. et al. Stroke associated with atrial fibrillation incidence and early outcomes in the north Dublin population stroke study // Cerebrovasc. Dis. - 2010. - Vol. 29. - P. 43-49.
5. Gladstone D.J., Bui E., Fang J. et al. Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated // Stroke. - 2009. - Vol. 40. - P. 235-240.
6. Hart R.G., Pearce L.A., Rothbart R.M. et al. Stroke With Intermittent Atrial Fibrillation: Incidence and Predictors During Aspirin Therapy // J. Am. Coll. Cardiol. - 2000. - Vol. 35. - P. 183-187.
7. Flaker G.C., Belew K., Beckman K. and the AFFIRM Investigators. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study // Am. Heart J. - 2005. - Vol. 149. - P. 657-663.
8. Сулимов В.А., Голицин С.П., Панченко Е.П. и соавт. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК и ВНОА, 2011 // Рациональная фармакотерапия в кардиологии. - 2011. - Т. 7, № 4, приложение. - С. 3-79.
9. Сулимов В.А., Голицин С.П., Панченко Е.П. и соавт. Диагностика и лечение фибрилляции предсердий // Рекомендации РКО, ВНОА и АССХ. - М., 2012. - 100 с.
10. Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation // Europ. Heart J. - 2010. - Vol. 31. - P. 2369-2429.
11. Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation // Europ. Heart J. - 2012. - [Электронный ресурс] doi:10.1093/eurheartj/ehs253
12. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the Euro Heart Survey on atrial fibrillation // Chest. - 2010. - Vol. 137. - P. 263-272.
13. Connolly S.J., Eikelboom J., Joyner C. et al. Apixa-ban in Patients with Atrial Fibrillation // N. Engl. J. Med. - 2011. - Vol. 364. - P. 806-817.
14. Connolly S.J., Eikelboom J., Hirsh J. et al. ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable // Ann. Intern. Med. - 2011. - Vol. 155. - P. 579-586.
15. Link K.P. The discovery of dicumarol and its sequels // Circulation. - 1959. - Vol. 19. - P. 97-107.
16. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation // Ann. Intern. Med. - 2007. - Vol. 146. - P. 857-867.
17. Connolly S.J., Pogue J., Hart A. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controllled trial // Lancet. - 2006. - Vol. 367. - P. 1903-1912.
18. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation // N. Engl. J. Med. - 2009. - Vol. 361. - P. 1139-1151.
19. ROCKET AF Study Investigators. Rivaroxaban - once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study // Am. Heart J. - 2010. - Vol. 159. - P. 340-347.
20. Patel M.R., Mahaffey K.W., Garg J. et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in non-valvular atrial fibrillation // N. Engl. J. Med. - 2011. - Vol. 365. - P. 883-891.
21. Granger C.B., Alexander J.H., McMurray J.J. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. - 2011. - Vol. 365, № 11. - P. 981.
22. Heidbuchel H., Verhamme P., Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation // Europace. - 2013. - Vol. 15. - P. 625-651. - [Электронный ресурс] doi:10.1093/europace/eut083
Review
For citations:
Novikova T.N. STROKE PREVENTION IN NON-VALVULAR FORM OF ATRIAL FIBRILLATION. Translational Medicine. 2014;(2):5-12. (In Russ.) https://doi.org/10.18705/2311-4495-2014-0-2-97-104
Views:
693
Email this article 